Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BPMC NASDAQ:RARE NASDAQ:SDGR NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$34.99-1.2%$31.63$25.17▼$36.60$5.90B0.311.84 million shs2.15 million shsBPMCBlueprint Medicines$129.46$128.90$84.25▼$129.65$8.36B0.893.86 million shsN/ARAREUltragenyx Pharmaceutical$26.120.0%$22.68$18.29▼$42.37$2.57B0.391.75 million shs1.56 million shsSDGRSchrodinger$13.13-1.1%$12.09$10.94▼$27.63$980.40M1.571.62 million shs1.78 million shsZLABZai Lab$18.60-5.9%$20.23$15.96▼$44.34$2.24B0.85784,499 shs1.25 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%+5.01%+1.81%+1.40%+16.58%BPMCBlueprint Medicines0.00%0.00%0.00%0.00%+29.67%RAREUltragenyx Pharmaceutical0.00%+5.83%+12.87%+5.79%-21.82%SDGRSchrodinger0.00%+11.04%+15.48%-1.56%-44.03%ZLABZai Lab0.00%-8.69%-7.62%+9.78%-30.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$34.99-1.2%$31.63$25.17▼$36.60$5.90B0.311.84 million shs2.15 million shsBPMCBlueprint Medicines$129.46$128.90$84.25▼$129.65$8.36B0.893.86 million shsN/ARAREUltragenyx Pharmaceutical$26.120.0%$22.68$18.29▼$42.37$2.57B0.391.75 million shs1.56 million shsSDGRSchrodinger$13.13-1.1%$12.09$10.94▼$27.63$980.40M1.571.62 million shs1.78 million shsZLABZai Lab$18.60-5.9%$20.23$15.96▼$44.34$2.24B0.85784,499 shs1.25 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%+5.01%+1.81%+1.40%+16.58%BPMCBlueprint Medicines0.00%0.00%0.00%0.00%+29.67%RAREUltragenyx Pharmaceutical0.00%+5.83%+12.87%+5.79%-21.82%SDGRSchrodinger0.00%+11.04%+15.48%-1.56%-44.03%ZLABZai Lab0.00%-8.69%-7.62%+9.78%-30.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.82Moderate Buy$45.2129.22% UpsideBPMCBlueprint Medicines 2.00Hold$130.600.88% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$60.41131.29% UpsideSDGRSchrodinger 2.33Hold$20.5056.13% UpsideZLABZai Lab 2.63Moderate Buy$45.83146.42% UpsideCurrent Analyst Ratings BreakdownLatest BPMC, ALKS, RARE, ZLAB, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026RAREUltragenyx Pharmaceutical GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.005/8/2026ZLABZai Lab CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $44.005/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.005/6/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$43.00 ➝ $44.005/6/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.005/6/2026RAREUltragenyx Pharmaceutical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $47.005/6/2026RAREUltragenyx Pharmaceutical WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$27.00 ➝ $26.004/29/2026RAREUltragenyx Pharmaceutical BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $43.004/27/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/27/2026ALKSAlkermes Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B3.95$1.66 per share21.14$10.51 per share3.33BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54RAREUltragenyx Pharmaceutical$673M3.82N/AN/A($2.40) per share-10.88SDGRSchrodinger$255.87M3.79N/AN/A$4.25 per share3.09ZLABZai Lab$460.16M4.58N/AN/A$6.39 per share2.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9038.8851.46N/A9.78%9.26%5.66%7/28/2026 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%N/ARAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-2,272.48%-45.78%N/ASDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%N/AZLABZai Lab-$175.54M-$1.61N/AN/AN/A-39.29%-23.57%-15.29%N/ALatest BPMC, ALKS, RARE, ZLAB, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 million2/26/2026Q4 2025ALKSAlkermes$0.43$0.29-$0.14$0.29$380.44 million$384.55 million2/26/2026Q4 2025ZLABZai Lab-$0.44-$0.46-$0.02-$0.50$122.67 million$127.60 million2/25/2026Q4 2025SDGRSchrodinger-$0.13$0.44+$0.57$0.44$83.66 million$87.24 million2/14/2026Q4 2025ALKSAlkermesN/A$0.29N/A$0.29N/A$384.55 million2/14/2026Q4 2025ZLABZai LabN/A-$0.50N/A-$0.50N/A$127.60 million2/12/2026Q4 2025RAREUltragenyx Pharmaceutical-$1.20-$1.29-$0.09-$1.29$199.60 million$207.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.273.19BPMCBlueprint Medicines1.012.802.75RAREUltragenyx PharmaceuticalN/A2.022.34SDGRSchrodingerN/A2.742.75ZLABZai LabN/A2.452.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BPMCBlueprint MedicinesN/ARAREUltragenyx Pharmaceutical97.67%SDGRSchrodinger79.05%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%BPMCBlueprint Medicines4.21%RAREUltragenyx Pharmaceutical5.20%SDGRSchrodinger21.00%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.20 millionOptionableSDGRSchrodinger79073.82 million58.32 millionOptionableZLABZai Lab1,784113.41 million107.79 millionOptionableBPMC, ALKS, RARE, ZLAB, and SDGR HeadlinesRecent News About These CompaniesZai Lab Q1 Earnings Call Highlights12 minutes ago | marketbeat.comZai Lab (NASDAQ:ZLAB) Given New $44.00 Price Target at CitigroupMay 8 at 3:50 PM | marketbeat.comZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7 at 11:00 PM | seekingalpha.comZai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings ResultsMay 7 at 10:49 PM | marketbeat.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7 at 10:31 AM | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7 at 7:24 AM | finance.yahoo.comZai Lab (ZLAB) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comAssessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetApril 29, 2026 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comZai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor CallApril 26, 2026 | marketbeat.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - SlideshowApril 22, 2026 | seekingalpha.comZai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What HappenedApril 22, 2026 | marketbeat.comZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026April 22, 2026 | businesswire.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases TranscriptApril 20, 2026 | seekingalpha.comZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesApril 18, 2026 | businesswire.comZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and ...April 18, 2026 | finance.yahoo.comZai Lab stock rises on positive trial data for cancer drugApril 18, 2026 | in.investing.comZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasApril 17, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Time to Buy?April 17, 2026 | marketbeat.comZai Lab Limited - Depositary Receipt (ZLAB) price target increased by 19.30% to 26.69April 15, 2026 | msn.comBoehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasApril 15, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Here's Why the AI Infrastructure Story Is Just Getting Bigger for GOOGLBy Ryan Hasson | April 21, 2026USA Rare Earth's $2.8B Power Play to Secure the Supply ChainBy Jeffrey Neal Johnson | April 23, 20263 Stocks Flashing Rare Buy Signals After the Market's Wildest MonthBy Bridget Bennett | April 21, 2026Investing in Rare Earth Elements: How the REXC ETF Bypasses China’s DominanceBy Jessica Mitacek | April 28, 2026BPMC, ALKS, RARE, ZLAB, and SDGR Company DescriptionsAlkermes NASDAQ:ALKS$34.99 -0.41 (-1.16%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$34.97 -0.02 (-0.07%) As of 05/8/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Blueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Ultragenyx Pharmaceutical NASDAQ:RARE$26.12 -0.01 (-0.04%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$26.84 +0.72 (+2.74%) As of 05/8/2026 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Schrodinger NASDAQ:SDGR$13.13 -0.15 (-1.13%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$13.23 +0.10 (+0.78%) As of 05/8/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Zai Lab NASDAQ:ZLAB$18.60 -1.16 (-5.87%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$18.70 +0.10 (+0.54%) As of 05/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
